Literature DB >> 22915812

N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization.

Scott B Biering1, Andrew Huang, Andy T Vu, Lindsey R Robinson, Birgit Bradel-Tretheway, Eric Choi, Benhur Lee, Hector C Aguilar.   

Abstract

Nipah virus (NiV) is the deadliest known paramyxovirus. Membrane fusion is essential for NiV entry into host cells and for the virus' pathological induction of cell-cell fusion (syncytia). The mechanism by which the attachment glycoprotein (G), upon binding to the cell receptors ephrinB2 or ephrinB3, triggers the fusion glycoprotein (F) to execute membrane fusion is largely unknown. N-glycans on paramyxovirus glycoproteins are generally required for proper protein conformational integrity, transport, and sometimes biological functions. We made conservative mutations (Asn to Gln) at the seven potential N-glycosylation sites in the NiV G ectodomain (G1 to G7) individually or in combination. Six of the seven N-glycosylation sites were found to be glycosylated. Moreover, pseudotyped virions carrying these N-glycan mutants had increased antibody neutralization sensitivities. Interestingly, our results revealed hyperfusogenic and hypofusogenic phenotypes for mutants that bound ephrinB2 at wild-type levels, and the mutant's cell-cell fusion phenotypes generally correlated to viral entry levels. In addition, when removing multiple N-glycans simultaneously, we observed synergistic or dominant-negative membrane fusion phenotypes. Interestingly, our data indicated that 4- to 6-fold increases in fusogenicity resulted from multiple mechanisms, including but not restricted to the increase of F triggering. Altogether, our results suggest that NiV-G N-glycans play a role in shielding virions against antibody neutralization, while modulating cell-cell fusion and viral entry via multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915812      PMCID: PMC3486489          DOI: 10.1128/JVI.01304-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance.

Authors:  S Olofsson; J E Hansen
Journal:  Scand J Infect Dis       Date:  1998

2.  Differential rates of protein folding and cellular trafficking for the Hendra virus F and G proteins: implications for F-G complex formation.

Authors:  Shannon D Whitman; Everett Clinton Smith; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

3.  EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.

Authors:  Oscar A Negrete; Ernest L Levroney; Hector C Aguilar; Andrea Bertolotti-Ciarlet; Ronen Nazarian; Sara Tajyar; Benhur Lee
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

4.  Interactions of human complement with virus particles containing the Nipah virus glycoproteins.

Authors:  John B Johnson; Hector C Aguilar; Benhur Lee; Griffith D Parks
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

5.  Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus.

Authors:  Michelle L Colgrave; Hayley J Snelling; Brian J Shiell; Yan-Ru Feng; Yee-Peng Chan; Katharine N Bossart; Kai Xu; Dimitar B Nikolov; Christopher C Broder; Wojtek P Michalski
Journal:  Glycobiology       Date:  2011-12-14       Impact factor: 4.313

Review 6.  Nipah virus--a potential agent of bioterrorism?

Authors:  Sai-Kit Lam
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion.

Authors:  Veronika von Messling; Roberto Cattaneo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2.

Authors:  Thomas A Bowden; A Radu Aricescu; Robert J C Gilbert; Jonathan M Grimes; E Yvonne Jones; David I Stuart
Journal:  Nat Struct Mol Biol       Date:  2008-05-18       Impact factor: 15.369

10.  Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007.

Authors:  Stephen P Luby; M Jahangir Hossain; Emily S Gurley; Be Nazir Ahmed; Shakila Banu; Salah Uddin Khan; Nusrat Homaira; Paul A Rota; Pierre E Rollin; James A Comer; Eben Kenah; Thomas G Ksiazek; Mahmudur Rahman
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more
  32 in total

1.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Stimulation of Nipah Fusion: Small Intradomain Changes Trigger Extensive Interdomain Rearrangements.

Authors:  Priyanka Dutta; Ahnaf Siddiqui; Mohsen Botlani; Sameer Varma
Journal:  Biophys J       Date:  2016-10-18       Impact factor: 4.033

3.  Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

Authors:  Blair L DeBuysscher; Dana Scott; Andrea Marzi; Joseph Prescott; Heinz Feldmann
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

4.  Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.

Authors:  J Lizbeth Reyes Zamora; Victoria Ortega; Gunner P Johnston; Jenny Li; Nicole M André; I Abrrey Monreal; Erik M Contreras; Gary R Whittaker; Hector C Aguilar
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

5.  Attachment protein G of an African bat henipavirus is differentially restricted in chiropteran and nonchiropteran cells.

Authors:  Nadine Krüger; Markus Hoffmann; Jan Felix Drexler; Marcel Alexander Müller; Victor Max Corman; Christian Drosten; Georg Herrler
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

6.  Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.

Authors:  Birgit G Bradel-Tretheway; J Lizbeth Reyes Zamora; Jacquelyn A Stone; Qian Liu; Jenny Li; Hector C Aguilar
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

7.  Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.

Authors:  Birgit G Bradel-Tretheway; Qian Liu; Jacquelyn A Stone; Samantha McInally; Hector C Aguilar
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

8.  Nipah virion entry kinetics, composition, and conformational changes determined by enzymatic virus-like particles and new flow virometry tools.

Authors:  Matthew Landowski; Jeffrey Dabundo; Qian Liu; Anthony V Nicola; Hector C Aguilar
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

9.  Individual N-glycans added at intervals along the stalk of the Nipah virus G protein prevent fusion but do not block the interaction with the homologous F protein.

Authors:  Qiyun Zhu; Scott B Biering; Anne M Mirza; Brittany A Grasseschi; Paul J Mahon; Benhur Lee; Hector C Aguilar; Ronald M Iorio
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

10.  Multiple Strategies Reveal a Bidentate Interaction between the Nipah Virus Attachment and Fusion Glycoproteins.

Authors:  Jacquelyn A Stone; Bhadra M Vemulapati; Birgit Bradel-Tretheway; Hector C Aguilar
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.